Skip to main
BTSG

BTSG Stock Forecast & Price Target

BTSG Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrightSpring Health Services Inc. has demonstrated robust performance in its OP Rehab segment, showcasing a growth rate in the double-digit percentage range while generating appealing margins. Management is optimistic about improving these margins further over time through operational efficiencies and strategic mergers and acquisitions, which could significantly enhance EBITDA. The company's strong market share in the generic drug sector and continued positive EBITDA projections for 2026-2027, driven by specialty pharmacy growth and operational initiatives, suggest a favorable outlook for BrightSpring Health's financial performance.

Bears say

BrightSpring Health Services Inc. faces significant revenue risks tied to potential reductions in client budgets and a reliance on prescription writing, which could adversely impact its revenues and cash flows. The company's acquisition of home health locations, while promising for future EBITDA growth, may not be sufficiently capitalized due to a heavy debt load that restricts investment in expansion efforts. Furthermore, competitive pressures from other healthcare providers could hinder BrightSpring's market growth and patient acquisition, contributing to a cautious overall financial outlook.

BTSG has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BrightSpring Health Services Inc (BTSG) Forecast

Analysts have given BTSG a Buy based on their latest research and market trends.

According to 9 analysts, BTSG has a Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BrightSpring Health Services Inc (BTSG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.